Targeted UCAR-T cell therapy for advanced glioma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the safety and initial efficacy of targeted IL-13Rα2 or B7-H3 UCAR-T cell injections in patients with advanced glioma. Participants will receive these targeted therapies to assess their pharmacokinetics and the biomarkers associated with efficacy and safety. The study will include patients who have previously failed standard treatments and will monitor their response to the new therapy. The trial will also analyze the characteristics of the metabolites after single and multiple administrations.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 18-70 years old, male or female, and the expected survival period is not less than 3 months.
* Advanced, locally advanced or recurrent tumor diagnosed histologically or cytologically.
* Failed in previous standard treatment or gived up treatment for various reasons after failure of first-line treatment.
* Failed in therapy by PD-1 or PD-L1 antibody or stopped administration of PD-1 or PD-L1 antibody for more than 4 weeks.
* At least 1 measurable target lesion (RECIST v1.1).
* 0-2 in ECOG physical state score.
* Available initial or recurrent tumor tissue for at least 10 stanable and detectable sections.
* Blood routine test: WBC ≥ 3×10\^9/L, lymphocyte percentage (LY%) ≥ 15%, hemoglobin Hbo (Hb) ≥ 90g/L, platelet (PLT) ≥ 60×10\^9/L.
* Liver and kidney functions: alanine transaminase (ALT) and aspartate transaminase (AST) \< 3 times of the normal value, total bilirubin (TBiL) \< 1.5 times of the normal value, serum creatinine (SCR) \< 1.5 times of the normal value.
* IL-13Rα2 or B7-H3 antigen expression \> 50%.
* Volunteered to enroll this study and signed the informed consent with good compliance and cooperation with follow-up.
* Experienced radiotherapy and chemotherapy with an interval of more than 4 week.

Exclusion Criteria:

* Hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) positive and peripheral blood HBV DNA titer ≥ 5 × 10\^2 copies/L; HCV antibody and peripheral blood HCV RNA positive; Human immunodeficiency virus (HIV) antibody positive; CMV DNA test positive; Syphilis test positive.
* Experienced any gene therapy previously.
* Needing long-term immunosuppressants for any reason.
* Any serious and uncontrolled systemic autoimmune disease or any unstable systemic disease, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, ulcerative colitis, Crohn's disease and temporal arteritis.
* Severe heart, lung, liver and kidney insufficiency or severe debilitating lung disease; Cardiac function: Grade III or above according to NYHA standard; Liver function: grade C in Child-Puge grading standard; Renal function: chronic kidney disease (CKD) more than stage 4; Renal insufficiency above stage Ⅲ; Lung function: symptoms of severe respiratory failure, involving other organs; Brain function: abnormality of central nervous system or disturbance of consciousness.
* Administrating of systematical steroids currently (except usage inhaled steroids recently or currently).
* Pregnancy and lactation (the safety of this treatment for unborn children is not clear, and female participants with reproductive potential must have negative serum or urine pregnancy test within 48 hours before administration).
* Allergy to immunotherapy and related drugs.
* Complicated with another tumor.
* History of organ transplantation or waiting for organ transplantation.
* After evaluation by researcher,noncompliance with the requirements of the study protocol was confirmed.

Where it's running

• The Second Affiliated Hospital of Soochow University
  Suzhou, Jiangsu, China Recruiting

Study contacts

• Study coordinator: Qing Lan, Doctor
• Email: szlq006@163.com
• Phone: +86-512-67784087

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Natural history of atypical parkinsonian syndromes: a multi-center observation

  This study follows people with APS like MSA, DLB, PSP, and CBD to see how their symptoms and brain images change over time.

  Recruiting at 6 sites Second Affiliated Hospital of Soochow University · Changshu, Jiangsu and 19 other locations · NCT07805967

• Azacitidine, Chidamide, and PD-1 antibody in relapsed/refractory PTCL

  This study tests a combination of azacitidine, chidamide, and a PD-1 antibody to see if it helps adults with relapsed or refractory peripheral T-cell lymphoma.

  Recruiting Early Phase 1 Second Affiliated Hospital of Soochow University · Suzhou · NCT07598578

• PRaG-1 Plus PRaG Therapy with Radiation and Immunotherapy in Older Adults with Advanced Solid Tumors

  This study tests whether giving PRaG-1 Cordycepin tablets together with radiation, immune-boosting injections, and PD-1/PD-L1 inhibitors can help people aged 65 and older with advanced solid tumors.

  Recruiting Phase 2 Second Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT07267234

• Cordycepin (PRaG-1) to raise CD8+ T‑cell counts after treatment for solid tumors

  This trial will test whether PRaG-1 (cordycepin) can raise low CD8+ T‑cell counts in adults who are tumor‑free after treatment for solid cancers.

  Recruiting Phase 2 Second Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT07258160

• Tirofiban plus dual antiplatelet therapy for mild stroke

  This trial will test whether giving intravenous tirofiban within 48 hours followed by two oral antiplatelet medicines helps adults with mild non‑cardioembolic ischemic stroke (NIHSS ≤5) achieve excellent recovery more often than standard dual antiplatelet therapy.

  Recruiting at 18 sites Phase 4 Second Affiliated Hospital of Soochow University · Suzhou, Anhui and 17 other locations · NCT07095790

• Selinexor with high-dose methotrexate, rituximab, and low-dose whole-brain radiotherapy for newly diagnosed CNS lymphoma patients who can't have transplant

  We will test whether adding oral selinexor to high-dose methotrexate and rituximab followed by low-dose whole-brain radiotherapy can help people with newly diagnosed central nervous system lymphoma who are not candidates for stem cell transplant.

  Recruiting Phase 2 Second Affiliated Hospital of Soochow University · Suzhou · NCT07002099

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.